T4K3.news

Bristol-Myers Squibb and Pfizer stocks rise after Eliquis discount announcement

BMY and PFE stocks increased after announcing a discount on the blood thinner Eliquis.

July 17, 2025 at 01:47 PM

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount

Bristol-Myers Squibb and Pfizer stocks saw gains following the announcement of Eliquis discounts.

Bristol-Myers Squibb and Pfizer stocks rise after Eliquis discount announcement

Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced plans to sell their blood thinner Eliquis directly to patients at a discounted price, a move aimed at making the medication more affordable. The discount, approximately 40% off the list price, follows discussions with the Trump administration to lower drug prices. Patients can order a 30-day supply of Eliquis for $346 through the Eliquis 360 Support website, down from the normal price of $606. Following this news, BMY shares rose by 0.36% and PFE shares increased by 0.1%. Both companies aim to increase access and affordability for patients, as stated by BMY CEO Christopher Boerner.

Key Takeaways

✔️

BMY and PFE stocks increased following Eliquis discount announcement

✔️

Direct sales to patients aim to reduce drug costs by 40%

✔️

CEO emphasizes commitment to patient access and affordability

✔️

Stock trends show BMY declining while PFE remains slightly more favored

"The BMS-Pfizer Alliance is committed to increasing patient access and affordability."

CEO Christopher Boerner highlights the companies' dedication to making medications accessible to patients.

"Patients can now order a 30-day supply of Eliquis for $346, down from $606."

This new pricing strategy aims to alleviate the financial burden on patients needing this medication.

The decision to lower Eliquis prices reflects a growing trend among pharmaceutical companies to respond to public pressure for more affordable medications. This move not only boosts patient accessibility but also positively impacts stock performance. However, investors should remain cautious; while the current gains may seem encouraging, stock performance for both companies has shown volatility throughout the year. The effectiveness of this discount strategy in sustaining stock prices remains to be seen.

Highlights

Affordable healthcare is crucial for patient access.
Direct-to-patient sales could change drug pricing.
Lower prices mean better access for those in need.
Investors should watch how discounts affect stock performance.

Potential financial risk due to pricing strategy

The significant discount on Eliquis raises concerns about the long-term financial impact on both companies. Investors may be wary of sustaining revenues while lowering drug prices could create backlash from stakeholders focused on profit margins.

The pharmaceutical industry's approach to pricing could reshape patient access significantly in the coming months.

🏷️

eliquis pharmaceutical stocks investing pricing business finance healthcare

Enjoyed this? Let your friends know!